Finished
Prehabilitation Plus ERAS in Gastric Cancer Surgery
NCT07328633 · The Affiliated Hospital of Qingdao University · Updated 9 Jan 2026
- What is being tested
- Pre-habilitation Program; Enhanced Recovery After Surgery (ERAS) Protocol
- For
- Gastric Cancer (GC)
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 75 years. About 136 people. The full rules are on the registry page.
- Where
- China
- When
- Starts or started 5 Dec 2024, ends 30 Sept 2025. Registered 9 Jan 2026.
- Results
- None posted yet.
In the researchers' words
This study aims to evaluate the impact of pre-habilitation combined with Enhanced Recovery After Surgery (ERAS) versus ERAS perioperative management alone on clinical outcomes in patients with gastric cancer undergoing neoadjuvant chemotherapy and laparoscopic (robotic) gastrectomy. The study is a single-center, randomized controlled trial involving patients aged 18-75 years. Participants will be randomly assigned to either a pre-habilitation program plus ERAS or ERAS alone. The primary outcome is the incidence of postoperative complications within 30 days. Secondary outcomes include pathological data, surgical outcomes, patient-reported outcomes, and long-term survival rates.
Sites
- The Affiliated Hospital of Qingdao UniversityQingdao, Shandong, China